var data={"title":"Combination beta-lactamase inhibitors, carbapenems, and monobactams","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Combination beta-lactamase inhibitors, carbapenems, and monobactams</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/contributors\" class=\"contributor contributor_credentials\">Alyssa R Letourneau, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/contributors\" class=\"contributor contributor_credentials\">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/contributors\" class=\"contributor contributor_credentials\">Allyson Bloom, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 07, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The spectrum of activity and pharmacology of combination beta-lactamase inhibitors, carbapenems, and monobactams will be reviewed here. The mechanisms of action and resistance and major adverse reactions of the beta-lactam antibiotics, issues related to penicillins and cephalosporins are discussed separately. (See <a href=\"topic.htm?path=beta-lactam-antibiotics-mechanisms-of-action-and-resistance-and-adverse-effects\" class=\"medical medical_review\">&quot;Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects&quot;</a> and <a href=\"topic.htm?path=penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins\" class=\"medical medical_review\">&quot;Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins&quot;</a> and <a href=\"topic.htm?path=cephalosporins\" class=\"medical medical_review\">&quot;Cephalosporins&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">BETA-LACTAMASE INHIBITOR COMBINATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clavulanate, sulbactam, tazobactam, avibactam, and vaborbactam are beta-lactamase inhibitors that have little intrinsic antibacterial activity but inhibit the activity of a number of plasmid-mediated beta-lactamases [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/1\" class=\"abstract_t\">1</a>]. Only avibactam inhibits chromosomally mediated AmpC beta-lactamases, and none inhibit the class B metallo-carbapenemases, such as New Delhi metallo-beta-lactamase [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/2\" class=\"abstract_t\">2</a>]. Combination of these agents with <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a>, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, <a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">piperacillin</a>, ceftolozane, <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a>, and <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> results in antibiotics with an enhanced spectrum of activity against many, but not all, organisms containing plasmid-mediated beta-lactamases. The addition of avibactam to ceftazidime and vaborbactam to meropenem results in enhanced activity against many, but not all, organisms producing carbapenemases. In addition, sulbactam and tazobactam inhibit the chromosomal beta-lactamase of many <em>Bacteroides</em> species, extending the spectrum of coverage of combinations with these compounds to include <em>Bacteroides</em> as well.</p><p>Dosing of combination beta-lactam beta-lactamase inhibitors is listed separately, and the dosing should be modified in the setting of renal failure (<a href=\"image.htm?imageKey=ID%2F51241\" class=\"graphic graphic_table graphicRef51241 \">table 1</a>). For <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-drug-information\" class=\"drug drug_general\">piperacillin-tazobactam</a>, an extended infusion (eg, 3.375 g infused over four hours every eight hours) is an alternative to standard dosing; in particular, this strategy has been used for critically ill patients or for pathogens with elevated but susceptible minimum inhibitory concentrations. The benefits of extended infusion over standard dosing have been suggested by some studies but not all [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/3,4\" class=\"abstract_t\">3,4</a>]. Overall, this dosing regimen is at least equivalent and may be superior to standard dosing in appropriate patient populations. (See <a href=\"topic.htm?path=prolonged-infusions-of-beta-lactam-antibiotics\" class=\"medical medical_review\">&quot;Prolonged infusions of beta-lactam antibiotics&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H95654503\"><span class=\"h2\">Amoxicillin-clavulanate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=amoxicillin-and-clavulanate-drug-information\" class=\"drug drug_general\">Amoxicillin-clavulanate</a> will inhibit most strains of oxacillin-sensitive <em>Staphylococcus aureus</em> and beta-lactamase producing <em>Haemophilus influenzae</em> in addition to the usual organisms inhibited by <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a> alone (see <a href=\"topic.htm?path=penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins\" class=\"medical medical_review\">&quot;Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins&quot;</a>). At the high drug concentrations achieved in urine, the combination is also active against certain beta-lactamase producing Enterobacteriaceae. Amoxicillin-clavulanate (250 to 500 mg PO Q 8h or 875 mg PO Q12h) can be used as oral therapy for patients with otitis media, sinusitis, lower respiratory infections, bite wounds, and urinary tract infections [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/5\" class=\"abstract_t\">5</a>], although there are no data that this combination is superior to other antibiotics (such as <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> or the second or third generation oral cephalosporins). (See <a href=\"topic.htm?path=soft-tissue-infections-due-to-dog-and-cat-bites\" class=\"medical medical_review\">&quot;Soft tissue infections due to dog and cat bites&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H95654485\"><span class=\"h2\">Ampicillin-sulbactam</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ampicillin-and-sulbactam-drug-information\" class=\"drug drug_general\">Ampicillin-sulbactam</a> is a parenteral formulation that expands the spectrum of <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a> to include most strains of <em>S. aureus</em> and beta-lactamase producing <em>H. influenzae</em>, some Enterobacteriaceae, and anaerobes (including <em>Bacteroides fragilis</em>). The sulbactam component of ampicillin-sulbactam has activity against many strains of <em>Acinetobacter baumannii</em>. Ampicillin-sulbactam has been used to treat patients with diabetic foot ulcers [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/6\" class=\"abstract_t\">6</a>]. This combination has also been used for prophylaxis and therapy of intra-abdominal and pelvic infections instead of <a href=\"topic.htm?path=cefoxitin-drug-information\" class=\"drug drug_general\">cefoxitin</a>. Randomized, double-blind trials showed ampicillin-sulbactam to be equivalent to cefoxitin in prophylaxis for abdominal surgery and in the treatment of intra-abdominal and pelvic infections [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/7,8\" class=\"abstract_t\">7,8</a>]. However, increasing resistance worldwide to ampicillin-sulbactam of both Enterobacteriaceae and <em>B. fragilis</em> in intra-abdominal infections renders this drug combination less useful for this purpose [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/9-11\" class=\"abstract_t\">9-11</a>]. </p><p class=\"headingAnchor\" id=\"H95654491\"><span class=\"h2\">Piperacillin-tazobactam</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-drug-information\" class=\"drug drug_general\">Piperacillin-tazobactam</a> expands the spectrum of <a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">piperacillin</a> to include beta-lactamase producing <em>S. aureus</em>, <em>H. influenzae</em>, <em>Neisseria gonorrhoeae</em>, some Enterobacteriaceae, and anaerobes (including <em>B. fragilis</em>) [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/12\" class=\"abstract_t\">12</a>]. This combination is generally not effective for piperacillin-resistant strains of <em>Pseudomonas aeruginosa</em>. In addition, piperacillin-tazobactam, dosed at 3.375 g every six hours, may not be an adequate dose for the treatment of <em>P. aeruginosa</em> infections. Thus, the spectrum and clinical utility of this agent is similar to <a href=\"topic.htm?path=ampicillin-and-sulbactam-drug-information\" class=\"drug drug_general\">ampicillin-sulbactam</a>, but it is preferred over ampicillin-sulbactam for intra-abdominal infection when an agent from this class is chosen. (See <a href=\"topic.htm?path=antimicrobial-approach-to-intra-abdominal-infections-in-adults#H721251431\" class=\"medical medical_review\">&quot;Antimicrobial approach to intra-abdominal infections in adults&quot;, section on 'Empiric antimicrobial therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H95654635\"><span class=\"h2\">Ceftolozane-tazobactam</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ceftolozane is a novel cephalosporin whose gram-negative activity is expanded by the addition of tazobactam. The combination has broad-spectrum in vitro activity against aerobic and facultative gram-negative bacilli, including <em>P. aeruginosa</em> and most extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. It has limited gram-positive activity against streptococci. Enterococcal and staphylococcal species are generally resistant. In clinical trials, clinical cure rates with <a href=\"topic.htm?path=ceftolozane-and-tazobactam-drug-information\" class=\"drug drug_general\">ceftolozane-tazobactam</a> were similar to those with <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> for complicated urinary tract infection caused by levofloxacin-susceptible organisms and, when combined with <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>, were similar to those with <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> for complicated intra-abdominal infections [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/13-16\" class=\"abstract_t\">13-16</a>]. Ceftolozane-tazobactam also performed favorably against infections caused by ESBL-producing isolates in these trials [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/17\" class=\"abstract_t\">17</a>]. It is also effective in treating carbapenem-resistant, ceftolozane-tazobactam susceptible <em>P. aeruginosa</em> pneumonia, as illustrated in a small multicenter, retrospective study [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/18\" class=\"abstract_t\">18</a>]. Efficacy of ceftolozane-tazobactam may be attenuated in patients with renal impairment (estimated glomerular filtration rate [GFR] &lt;50 <span class=\"nowrap\">mL/min)</span>. </p><p class=\"headingAnchor\" id=\"H527656792\"><span class=\"h2\">Ceftazidime-avibactam</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Avibactam is a novel broad-spectrum beta-lactamase inhibitor that has minimal antibacterial activity on its own. The addition of avibactam to <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a> extends the spectrum of activity to include most Enterobacteriaceae (including those that produce AmpC beta-lactamase, ESBL, and some <em>K. pneumoniae</em> and OXA-type carbapenemases) as well as <em>P. aeruginosa</em> species with high MICs to ceftazidime alone. <a href=\"topic.htm?path=ceftazidime-and-avibactam-drug-information\" class=\"drug drug_general\">Ceftazidime-avibactam</a> does not have activity against <em>Acinetobacter</em> species or organisms that produce metallo-beta-lactamases and is less active against anaerobes than other beta lactam-beta-lactamase combinations [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/19\" class=\"abstract_t\">19</a>]. In trials, the microbiological efficacy and clinical cure rates with ceftazidime-avibactam were similar to those with <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> for complicated urinary tract infection and, when combined with <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>, were overall similar to those with <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> for complicated intra-abdominal infections [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/20-22\" class=\"abstract_t\">20-22</a>]. The microbiological and clinical efficacy of ceftazidime-avibactam against isolates that were not ceftazidime susceptible also compared favorably with the carbapenem comparator.</p><p class=\"headingAnchor\" id=\"H1585176709\"><span class=\"h2\">Meropenem-vaborbactam</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Vaborbactam is a novel broad-spectrum beta-lactamase inhibitor that potently inhibits class A carbapenemases (including <em>K. pneumoniae</em> carbapenemases [KPC]). It is not active against class B or D carbapenemases (ie, metallo-beta-lactamases and OXA-type enzymes). The addition of vaborbactam to <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> reduces the MICs to meropenem among class A carbapenemase-producing Enterobacteriaceae to wild-type MIC levels [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/23,24\" class=\"abstract_t\">23,24</a>]. <a href=\"topic.htm?path=meropenem-and-vaborbactam-drug-information\" class=\"drug drug_general\">Meropenem-vaborbactam</a> was comparable to <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-drug-information\" class=\"drug drug_general\">piperacillin-tazobactam</a> in a trial of patients with complicated urinary tract infection [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/25\" class=\"abstract_t\">25</a>], and it is being evaluated in patients with bacteremia, hospital-acquired pneumonia, and complicated intraabdominal infections [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/26,27\" class=\"abstract_t\">26,27</a>]. The main role of this agent is for treatment of KPC-producing Enterobaceriaceae. Clinical data are thus far limited; an as yet unpublished randomized trial comparing meropenem-vaborbactam with the best available therapy for treatment of carbapenem-resistant Enterobacteriaceae infections was stopped early because of better outcomes in the meropenem-vaborbactam arm [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/26\" class=\"abstract_t\">26</a>]. </p><p>Vaborbactam does not enhance the clinical activity of <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> against carbapenem-resistant <em>P. aeruginosa</em> or <em>Acinetobacter</em> spp.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CARBAPENEMS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Carbapenems are generally resistant to cleavage by most plasmid and chromosomal beta-lactamases and have a very broad spectrum of activity encompassing [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/28,29\" class=\"abstract_t\">28,29</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gram-negative organisms (including beta-lactamase producing <em>H. influenzae</em> and <em>N. gonorrhoeae</em>, the Enterobacteriaceae, and <em>P. aeruginosa</em>), including those that produce extended-spectrum beta-lactamases</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anaerobes (including <em>B. fragilis</em>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gram-positive organisms (including <em>Enterococcus faecalis</em> and <em>Listeria</em>)</p><p/><p>Carbapenems are not generally active against <em>Stenotrophomonas maltophilia</em> (which has a carbapenem-hydrolyzing chromosomal beta-lactamase), <em>Burkholderia cepacia</em>, <em>Enterococcus faecium</em>, oxacillin-resistant staphylococci, or JK diphtheroids.</p><p>Although initial isolates of <em>P. aeruginosa</em> are usually susceptible to the carbapenems, resistance may emerge on therapy when these drugs are used as a single agent. Evidence suggests that carbapenems do not traverse the outer membrane of <em>P. aeruginosa</em> through the normal porin channel used by the other beta-lactams but rather through a different channel [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/30\" class=\"abstract_t\">30</a>]. Carbapenem-resistant strains of <em>P. aeruginosa</em> arising on therapy generally have altered permeability to these drugs and specific changes in their outer membrane proteins; such strains are generally not cross-resistant to other beta-lactams nor do they produce increased or novel beta-lactamase activity.</p><p>Carbapenem-hydrolyzing beta-lactamases have been increasingly isolated from gram-negative organisms and may limit therapy with these agents in these circumstances. (See <a href=\"topic.htm?path=beta-lactam-antibiotics-mechanisms-of-action-and-resistance-and-adverse-effects\" class=\"medical medical_review\">&quot;Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects&quot;</a> and <a href=\"topic.htm?path=overview-of-carbapenemase-producing-gram-negative-bacilli\" class=\"medical medical_review\">&quot;Overview of carbapenemase-producing gram-negative bacilli&quot;</a>.) </p><p>All carbapenems should be dose-reduced in the setting of renal dysfunction (<a href=\"image.htm?imageKey=ID%2F51241\" class=\"graphic graphic_table graphicRef51241 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Imipenem</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">Imipenem</a> is inactivated in the proximal renal tubule by the normal human enzyme renal dehydropeptidase I, with resultant low urinary levels of active drug and necrosis of the proximal tubule in the rabbit model. Such cleavage of imipenem is prevented by co-administration of cilastatin, a specific inhibitor of this dehydropeptidase. Imipenem-cilastatin (500 mg IV Q6h with normal renal function) is available for clinical use. The dosing of imipenem should be carefully titrated; patients with glomerular filtration rates of &lt;5 <span class=\"nowrap\">mL/min</span> should generally not receive imipenem unless hemodialysis is ongoing or will start within 48 hours.</p><p>Imipenem-cilastatin therapy has been associated with central nervous system (CNS) toxicity, including change in mental state, myoclonus, and seizures [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/31\" class=\"abstract_t\">31</a>]. In a meta-analysis of over 100 studies that compared <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> to a non-carbapenem antibiotic, imipenem use was associated with an excess of 4 seizures per 1000 patients treated [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/32\" class=\"abstract_t\">32</a>]. CNS toxicity with imipenem is especially evident in patients with underlying CNS disease or impaired renal function. Imipenem should not be used for the therapy of meningitis.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Meropenem</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">Meropenem</a> has a spectrum of activity similar to <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/33\" class=\"abstract_t\">33</a>]. Unlike imipenem, meropenem is stable to human renal dehydropeptidase I, so can be administered without cilastatin. Meropenem may have a slightly lower risk of producing seizures than imipenem-cilastatin, but that decrease has not been proven in direct head-to head comparisons of small sample size [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/32\" class=\"abstract_t\">32</a>]. Meropenem is useful for the treatment of bacterial meningitis (in pediatric patients &gt;3 months old) and intra-abdominal infection [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/34,35\" class=\"abstract_t\">34,35</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Ertapenem</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ertapenem-drug-information\" class=\"drug drug_general\">Ertapenem</a> is a newer carbapenem with a narrower spectrum of activity than <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> or <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a>. It is active against most Enterobacteriaceae and anaerobes but less active than the other carbapenems for <em>P. aeruginosa</em>, <em>Acinetobacter</em>, and Gram positive bacteria, particularly enterococci and penicillin-resistant pneumococci. The major benefit of ertapenem over other carbapenems is that it has a long half-life and can be administered once daily. Unlike meropenem, there are insufficient data to support the use of ertapenem for the therapy of meningitis.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Doripenem</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=doripenem-drug-information\" class=\"drug drug_general\">Doripenem</a> has demonstrated clinical efficacy in the treatment of complicated urinary tract and intra-abdominal infections [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/36,37\" class=\"abstract_t\">36,37</a>]. It has a similar spectrum of activity as <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a>, although it appears to have more potent in vitro activity against <em>P. aeruginosa</em> than meropenem [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/38,39\" class=\"abstract_t\">38,39</a>]. </p><p>In 2014, the US Food and Drug Administration (FDA) approved revisions to the <a href=\"topic.htm?path=doripenem-drug-information\" class=\"drug drug_general\">doripenem</a> label warning clinicians about increased mortality rates in patients with ventilator-associated bacterial pneumonia who received doripenem rather than <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a>, based on results of a randomized trial that was stopped early due to safety concerns [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/40\" class=\"abstract_t\">40</a>]. In the trial, 28-day all-cause mortality was higher and clinical response rates were lower with doripenem compared with imipenem, although different dosing regimens and use of adjunctive aminoglycosides may have influenced these results [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/41\" class=\"abstract_t\">41</a>]. (See <a href=\"topic.htm?path=treatment-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults#H8\" class=\"medical medical_review\">&quot;Treatment of hospital-acquired and ventilator-associated pneumonia in adults&quot;, section on 'Gram-negative pathogens'</a>.)</p><p>Further clinical trials are required to establish the efficacy and safety of <a href=\"topic.htm?path=doripenem-drug-information\" class=\"drug drug_general\">doripenem</a> in the setting of bacteremia and other severe infections.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">MONOBACTAMS (AZTREONAM)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">Aztreonam</a> (1 to 2 g IV Q8h) is a monocyclic beta-lactam antibiotic with good in vitro activity against the majority of gram-negative aerobic and facultative bacteria, including the Enterobacteriaceae and <em>P. aeruginosa </em>[<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/29,42\" class=\"abstract_t\">29,42</a>]. It has virtually no activity against gram-positive organisms or anaerobes; the majority of strains of <em>Acinetobacter</em> and <em>S. maltophilia</em> are resistant and resistant strains of <em>P. aeruginosa</em> frequently emerge during therapy with aztreonam alone. The spectrum of activity of aztreonam is similar to that of the aminoglycosides. However, it is less reliable therapy than aminoglycosides for the non-enteric gram-negative bacilli such as <em>Acinetobacter</em>, <em>P. aeruginosa</em>, and <em>S. maltophilia</em>. </p><p><a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">Aztreonam</a> is distinctive in that it is not degraded by the class B metallo-beta-lactamases, such as New Delhi metallo-beta-lactamase. (See <a href=\"topic.htm?path=overview-of-carbapenemase-producing-gram-negative-bacilli#H92008117\" class=\"medical medical_review\">&quot;Overview of carbapenemase-producing gram-negative bacilli&quot;, section on 'Metallo-beta-lactamases'</a>.)</p><p>Data support the absence of cross-allergenicity between <a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">aztreonam</a> and other beta-lactam antibiotics [<a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/43\" class=\"abstract_t\">43</a>]. However, patients with <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a> allergy may be allergic to aztreonam because of a shared side chain. The clinical situation in which aztreonam is most useful is in place of an extended spectrum penicillin or cephalosporin when these are indicated but cannot be used because of allergy. Aztreonam is the only monobactam currently marketed. Dose reductions are recommended in the setting of renal dysfunction (<a href=\"image.htm?imageKey=ID%2F51241\" class=\"graphic graphic_table graphicRef51241 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clavulanate, sulbactam, tazobactam, avibactam, and vaborbactam are beta-lactamase inhibitors that have little intrinsic antibacterial activity but inhibit the activity of a number of plasmid-mediated beta-lactamases. Combination of these agents with <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a>, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, <a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">piperacillin</a>, ceftolozane, or <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a> results in antibiotics with an enhanced spectrum of activity against many, but not all, organisms containing plasmid-mediated beta-lactamases. The addition of avibactam to ceftazidime and vaborbactam to <a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> results in enhanced activity against many, but not all, organisms producing carbapenemases. The sulbactam component of <a href=\"topic.htm?path=ampicillin-and-sulbactam-drug-information\" class=\"drug drug_general\">ampicillin-sulbactam</a> has activity against <em>Acinetobacter</em>. (See <a href=\"#H2\" class=\"local\">'Beta-lactamase inhibitor combinations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Carbapenems have a broad spectrum of activity against gram-negative organisms (including those that produce extended spectrum beta-lactamases), anaerobes (including <em>Bacteroides fragilis</em>), and gram-positive organisms (including <em>Enterococcus faecalis</em> and <em>Listeria</em>). When carbapenems are used as a single agent against initially susceptible isolates of <em>Pseudomonas aeruginosa</em>, resistance may emerge during therapy. (See <a href=\"#H3\" class=\"local\">'Carbapenems'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">Aztreonam</a> is a monocyclic beta-lactam with good in vitro activity against the majority of gram-negative aerobic and facultative bacteria, including the Enterobacteriaceae and <em>P. aeruginosa</em>, but virtually no activity against gram-positive organisms or anaerobes. However, when used alone for therapy of <em>P.</em> <em>aeruginosa</em> infection, resistance may emerge. Aztreonam has minimal cross-allergenicity with other beta-lactams with the exception of <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a>. (See <a href=\"#H8\" class=\"local\">'Monobactams (aztreonam)'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The dosing of these novel beta-lactams and dose modifications in patients with renal dysfunction (<a href=\"image.htm?imageKey=ID%2F51241\" class=\"graphic graphic_table graphicRef51241 \">table 1</a>) are important considerations in prescribing these drugs. </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/1\" class=\"nounderline abstract_t\">Bush LM, Johnson CC. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. Infect Dis Clin North Am 2000; 14:409.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/2\" class=\"nounderline abstract_t\">Sensakovic JW, Smith LG. Beta-lactamase inhibitor combinations. Med Clin North Am 1995; 79:695.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/3\" class=\"nounderline abstract_t\">Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/4\" class=\"nounderline abstract_t\">Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013; 56:272.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/5\" class=\"nounderline abstract_t\">Calver AD, Walsh NS, Quinn PF, et al. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group. Clin Infect Dis 1997; 24:570.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/6\" class=\"nounderline abstract_t\">McKinnon PS, Paladino JA, Grayson ML, et al. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1997; 24:57.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/7\" class=\"nounderline abstract_t\">Messick CR, Mamdani M, McNicholl IR, et al. Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections. Pharmacotherapy 1998; 18:175.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/8\" class=\"nounderline abstract_t\">Paladino JA, Rainstein MA, Serrianne DJ, et al. Ampicillin-sulbactam versus cefoxitin for prophylaxis in high-risk patients undergoing abdominal surgery. Pharmacotherapy 1994; 14:734.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/9\" class=\"nounderline abstract_t\">Liu CY, Huang YT, Liao CH, et al. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008; 52:3161.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/10\" class=\"nounderline abstract_t\">Hoban DJ, Bouchillon SK, Hawser SP, et al. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010; 54:3031.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/11\" class=\"nounderline abstract_t\">Hsueh PR, Badal RE, Hawser SP, et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2010; 36:408.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/12\" class=\"nounderline abstract_t\">Sanders WE Jr, Sanders CC. Piperacillin/tazobactam: a critical review of the evolving clinical literature. Clin Infect Dis 1996; 22:107.</a></li><li class=\"breakAll\">Zerbaxa (ceftolozane/tazobactam). US FDA approved product information. National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on January 08, 2015).</li><li class=\"breakAll\">Popejoy M, Cloutier D, Huntington J, et al. Ceftolozane/tazobactam for the treatment of cUTI and cIAI caused by ESBL-producing Enterobacteriaceae. Presented at IDWeek 2014, Philadelphia, PA, October 9, 2014. Abstract #260.</li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/15\" class=\"nounderline abstract_t\">Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385:1949.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/16\" class=\"nounderline abstract_t\">Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis 2015; 60:1462.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/17\" class=\"nounderline abstract_t\">Popejoy MW, Paterson DL, Cloutier D, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother 2017; 72:268.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/18\" class=\"nounderline abstract_t\">Munita JM, Aitken SL, Miller WR, et al. Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa. Clin Infect Dis 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/19\" class=\"nounderline abstract_t\">Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/&beta;-lactamase inhibitor combination. Drugs 2013; 73:159.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/20\" class=\"nounderline abstract_t\">Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis 2016; 62:1380.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/21\" class=\"nounderline abstract_t\">Vazquez JA, Gonz&aacute;lez Patz&aacute;n LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012; 28:1921.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/22\" class=\"nounderline abstract_t\">Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 16:661.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/23\" class=\"nounderline abstract_t\">Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/24\" class=\"nounderline abstract_t\">Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/25\" class=\"nounderline abstract_t\">Kaye KS, Bhowmick T, Metallidis S, et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA 2018; 319:788.</a></li><li class=\"breakAll\">https://clinicaltrials.gov/ct2/show/NCT02168946?term=vaborbactam&amp;rank=4 (Accessed on September 07, 2017).</li><li class=\"breakAll\">Vabomere (meropenem and vaborbactam injection). US FDA approved product information; Pasippany, NJ: The Medicines Company; August 2017.</li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/28\" class=\"nounderline abstract_t\">Norrby SR. Carbapenems. Med Clin North Am 1995; 79:745.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/29\" class=\"nounderline abstract_t\">Asbel LE, Levison ME. Cephalosporins, carbapenems, and monobactams. Infect Dis Clin North Am 2000; 14:435.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/30\" class=\"nounderline abstract_t\">Huang H, Hancock RE. Genetic definition of the substrate selectivity of outer membrane porin protein OprD of Pseudomonas aeruginosa. J Bacteriol 1993; 175:7793.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/31\" class=\"nounderline abstract_t\">Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84:911.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/32\" class=\"nounderline abstract_t\">Cannon JP, Lee TA, Clark NM, et al. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 2014; 69:2043.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/33\" class=\"nounderline abstract_t\">Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis 1995; 21:86.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/34\" class=\"nounderline abstract_t\">Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995; 21:544.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/35\" class=\"nounderline abstract_t\">Chang DC, Wilson SE. Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections. Am J Surg 1997; 174:284.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/36\" class=\"nounderline abstract_t\">Naber KG, Llorens L, Kaniga K, et al. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009; 53:3782.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/37\" class=\"nounderline abstract_t\">Lucasti C, Jasovich A, Umeh O, et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008; 30:868.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/38\" class=\"nounderline abstract_t\">Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67:1027.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/39\" class=\"nounderline abstract_t\">Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009; 49:291.</a></li><li class=\"breakAll\">US Food and Drug Administration. FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia. http://www.fda.gov/Drugs/DrugSafety/ucm387971.htm (Accessed on March 10, 2014).</li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/41\" class=\"nounderline abstract_t\">Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16:R218.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/42\" class=\"nounderline abstract_t\">Johnson DH, Cunha BA. Aztreonam. Med Clin North Am 1995; 79:733.</a></li><li><a href=\"https://www.uptodate.com/contents/combination-beta-lactamase-inhibitors-carbapenems-and-monobactams/abstract/43\" class=\"nounderline abstract_t\">Kishiyama JL, Adelman DC. The cross-reactivity and immunology of beta-lactam antibiotics. Drug Saf 1994; 10:318.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 482 Version 23.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H9\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">BETA-LACTAMASE INHIBITOR COMBINATIONS</a><ul><li><a href=\"#H95654503\" id=\"outline-link-H95654503\">Amoxicillin-clavulanate</a></li><li><a href=\"#H95654485\" id=\"outline-link-H95654485\">Ampicillin-sulbactam</a></li><li><a href=\"#H95654491\" id=\"outline-link-H95654491\">Piperacillin-tazobactam</a></li><li><a href=\"#H95654635\" id=\"outline-link-H95654635\">Ceftolozane-tazobactam</a></li><li><a href=\"#H527656792\" id=\"outline-link-H527656792\">Ceftazidime-avibactam</a></li><li><a href=\"#H1585176709\" id=\"outline-link-H1585176709\">Meropenem-vaborbactam</a></li></ul></li><li><a href=\"#H3\" id=\"outline-link-H3\">CARBAPENEMS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Imipenem</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Meropenem</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Ertapenem</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Doripenem</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">MONOBACTAMS (AZTREONAM)</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/482|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/51241\" class=\"graphic graphic_table\">- Dosing of parenteral beta-lactams for adult patients</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antimicrobial-approach-to-intra-abdominal-infections-in-adults\" class=\"medical medical_review\">Antimicrobial approach to intra-abdominal infections in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=beta-lactam-antibiotics-mechanisms-of-action-and-resistance-and-adverse-effects\" class=\"medical medical_review\">Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cephalosporins\" class=\"medical medical_review\">Cephalosporins</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-carbapenemase-producing-gram-negative-bacilli\" class=\"medical medical_review\">Overview of carbapenemase-producing gram-negative bacilli</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins\" class=\"medical medical_review\">Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prolonged-infusions-of-beta-lactam-antibiotics\" class=\"medical medical_review\">Prolonged infusions of beta-lactam antibiotics</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=soft-tissue-infections-due-to-dog-and-cat-bites\" class=\"medical medical_review\">Soft tissue infections due to dog and cat bites</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults\" class=\"medical medical_review\">Treatment of hospital-acquired and ventilator-associated pneumonia in adults</a></li></ul></div></div>","javascript":null}